DiscGenics

07/16/2024

We are excited to announce that the U.S. FDA has allowed the Phase III clinical evaluation of our allogeneic, injectable disc progenitor cell therapy (IDCT) for painful lumbar degenerative disc disease to proceed. Subject enrollment is expected to begin in Q4 2024.

/PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies...

07/09/2024

We are pleased to announce publication of results in the International Journal of Spine Surgery of our combined Phase 1/Phase 2 study of IDCT, our allogeneic, injectable disc progenitor cell therapy, for lumbar degenerative disc disease.

/PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies...

10/19/2023

We are proud to announce a research collaboration with the U.S. Department of Veterans Affairs for tissue-engineered discs with DiscGenics' proprietary Discogenic Cells. This project, led by Sarah Gullbrand, Ph.D. at the University of Pennsylvania, has been awarded BRAVE Funding by the VA Technology Transfer Program to support a large animal study of Discogenic Cell-derived implants.

In the words of Kevin Foley, M.D., DiscGenics' Chief Medical Officer and practicing neurosurgeon: "A biologic disc replacement in lieu of existing mechanical devices would continue to change the paradigm of spine care away from a device-centric model to one of disease modification through biologic and cell-based treatments."

Learn more here:

/PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that...

09/26/2023

We're thrilled to announce that our CEO, Flagg Flanagan, will be presenting at the East-West BioPharma Summit from Oct 2-4 and the 2023 Cell & Gene Meeting on the Mesa from Oct 10-12. Learn more about the event in our press release!

/PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that...

09/12/2023

We recently joined Merge Medical for an insightful podcast session where we delved deep into the transformative potential of DiscGenics and our pioneering Injectable Disc Cell Therapy (IDCT). Whether you're familiar with our mission or just getting to know us, this highlight video offers a concise overview of our vision and the groundbreaking work we're doing in the realm of spinal health.

04/17/2023

With IDCT we are aiming to impact millions of lives in a big way! Need proof? Check out Dr. Gornet's brief testimonial on the extraordinary possibilities.

01/26/2023

In rapid follow-up to this week’s announcement of our positive clinical results, we are delighted to announce the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Injectable Disc Cell Therapy (IDCT or rebonuputemcel) because of its potential to address the unmet medical needs of millions of patients with painful degenerative disc disease!

IDCT is the first and only product intended for spine care to receive this special regulatory designation. RMAT provides DiscGenics the opportunity for intensive FDA guidance on efficient development of IDCT.

Learn more: https://bit.ly/IDCT_RMAT and sign up for updates here: https://www.discgenics.com/contact

01/23/2023

We are pleased to announce positive two-year clinical data from our first-in-human clinical study of IDCT, an investigational allogeneic discogenic progenitor cell therapy for degenerative disc disease (DDD). In the study, IDCT safely increased disc volume and provided rapid, durable improvements in low back pain, function, quality of life, and pain medication usage out to two years post-injection in patients with early to moderate lumbar DDD. Learn more: https://prn.to/3R1jhjM and sign up for updates here: https://www.discgenics.com/contact

02/25/2022

We are thrilled to announce that DiscGenics Chief Medical Officer Kevin T. Foley, M.D., presented positive interim clinical data from our ongoing Phase I/II study of IDCT for degenerative disc disease (DDD) this morning at the Spine Summit 2022 in Las Vegas.

The key takeaway: High dose allogeneic injectable discogenic cell therapy (IDCT) was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection. Improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months.

We are in the process of analyzing data from patient follow-up visits at weeks 78 and 104 and intend to submit the full dataset to the U.S. FDA’s Office of Tissues and Advanced Therapies (OTAT) later this year. https://bit.ly/3tcqRwf